Loading...

Drug Efficiency Services and Precision Medicine

Drug Efficiency Services and Precision Medicine 2016-10-24T15:19:26+00:00

With our well-characterized Multiple Myeloma cellular model, Diag2Tec offers 3 types of services:

Assessment of drug efficiency and characterization of mechanism of action

Diag2tec provides to pharmaceutical and biotechnology companies a wide range of in vitro services to assess efficiency of new therapeutic drugs in our unique MM cell models and in other hematological cancers.

Identification of gene expression signature predictive of cancer cell-sensitivity to a given drug

The main goal is to achieve a precision medicine approach for multiple myeloma and other hematological cancers. Predictive biomarkers serve for different objectives like patient stratification in clinical development of a new drug or to help clinician in the choose of therapeutic treatment by predicting how a patient will react to a treatment.

In order to achieve this, we have developed innovative biomathematical algorithms (4 patents) to develop gene expression signatures (biomarkers) that is indicative for the prediction of cancer cells sensitivity or resistance to a given drug. The interest of the identified biomarkers to predict MM cell sensitivity or resistance to the different treatments have been validated using primary myeloma cells of patients cocultured with their bone marrow microenvironment as previously described.

To enhance our capacity to develop signature of prediction of tumor cell responses at a therapeutic agent, we have characterized our myeloma cell lines collection and the model of differentiation of normal plasma cells at different molecular levels using Gene Expression Profiling, RNA-seq, Exome-seq, Whole genome seq, Chip-seq (6 different histone marks), Single Nucleotide Polymorphism analysis, DNA methylation analysis and miRNA-seq. We also derived drug resistant myeloma cell lines (dexamethasone, bortezomib, IMiDs, melphalan, HDACi, …) and have characterized them using the same strategy.

Our cellular models and our computational expertise are major assets to offer to pharmaceutical and biotechnology companies the identification of biomarkers to predict sensitivity or resistance of MM or other hematological cancer cells to the different drugs investigated.

Identification of a personalized therapeutic treatment for each patient “chemogram”

We have developed a direct in vitro chemogram to test primary myeloma cell drug response to 5 – 10 molecules. We have taken advantage of our expertise in the understanding of MM cells and bone marrow microenvironment interactions and have develop an innovative and proprietary in vitro coculture model allowing primary MM cells culture in a supportive environment with the major growth factors cell to cell communication signals (in house coculture model). Today, our chemogram is miniaturized and automatized to test drug response of primary MM cells of patients to 5 – 10 molecules starting from bone marrow sample.

Today, we can offer a decision medical support to clinicians in order to propose targeted and precision therapy. This innovative tool has also a great interest for the follow-up of patient in medical analytical and testing laboratories.